Soham Das
Soham Das
PharmEasy attempted to stitch together companies from different segments of the healthcare ecosystem. Now, even as the government questions the legality of its core e-pharma business, the company finds itself simultaneously attempting to fight fires across its various, disparate business lines.
February 27, 2023
7 MINS READOn 16 February, India’s e-pharmacy sector woke to an all too familiar feeling—existential dread. As many as twenty players in the space—including Tata 1mg, Netmeds, and PharmEasy—were on the receiving end of show cause notices from the government which questioned the legality of their operations.
This isn’t the first time India’s e-pharmacies have been in the government’s crosshairs. With the central government yet to enshrine laws that specifically regulate the sale of medicines online, these businesses have always existed in a regulatory grey area, vulnerable to disruption. In 2018, the Delhi and Madras High Courts went so far as ordering e-pharmacies to temporarily cease operations.
For PharmEasy, the biggest e-pharma player in the country, the latest threats of regulatory action couldn’t have come at a worse time. After acquiring a trio of companies—e-pharma rival Medlife, healthcare supply chain platform Aknamed, and diagnostics chain Thyrocare—the company began readying for a public listing. In August 2022, nine months on from filing its draft red herring prospectus (DRHP), API Holdings—PharmEasy’s parent company— shelved its plans to go public altogether.
AgriTech
Premium Reads
By Vidhya Sivaramakrishnan
Analysis
Premium Reads
By Raghav Mahobe
Insurtech
Premium Reads
By Sohini Mitter
Analysis
Premium Reads
By Gaurav Tyagi
11 Min Read
By Vidhya Sivaramakrishnan
13 Min Read
By Raghav Mahobe
9 Min Read
By Sohini Mitter
12 Min Read
By Gaurav Tyagi
9 Min Read
By Nikhil Patwardhan
9 Min Read
By Pranav Balakrishnan